Eli Lilly, under pressure from Biohaven, launches head-to-head migraine trial between Emgality and Nurtec

As Biohaven’s fast-growing Nurtec ODT pressures rival migraine prevention medicines, one injectable player decided to bring the fight directly to the oral drug with a head-to-head clinical trial.